Author: 984562pwpadmin
-
Beyond APOE4: The Genetics of Personalized Prevention
How MTHFR and PEMT variants may reshape methylation, lipid transport, and phosphatidylcholine needs Karin Dee May 20, 2026 I want to talk about something that doesn’t get enough attention in the APOE4 community. We spend a lot of time discussing what to eat, which supplements to take, which labs to track. And that conversation matters.…
Written by
-
Blood Pressure: A Silent Contributor to Cognitive Decline
It doesn’t warn you. But it may be shaping your brain’s future every single day. Karin Dee Apr 16, 2026 We tend to pay attention to what we can feel. Pain. Fatigue. Brain fog. A racing heart. But blood pressure? It’s silent – while exerting a constant mechanical force on one of the most delicate…
Written by
-
APOE4, Cardiolipin and the Mitochondrial Roots of Alzheimer’s Risk
The case for SS-31, and why it’s part of my protocol Karin Dee Apr 23, 2026 We spend a lot of time in the Alzheimer’s space talking about amyloid, tau, inflammation, insulin resistance… and all of that matters. But upstream, there’s a potential failure in the making – one that doesn’t get nearly enough attention.…
Written by
-
Could Lithium Be a Missing Piece in Alzheimer’s Disease? A New Research Perspective
Karin Dee Feb 05, 2026 I’ve briefly touched on Lithium before – but it’s in the news again. A fascinating new study from Harvard Medical School is garnering attention across the neuroscience world for proposing something that might feel both surprising and logical, that lithium deficiency in the brain could be a driving factor in Alzheimer’s disease, and that restoring lithium…
Written by
-
My APOE4/4 Senolytic Protocol: Intermittent pulsing of Fisetin/Quercetin/Dasatinib to kill off “zombie” cells.
Why Senescent Cells Belong in the APOE4 Conversation Karin Dee Jan 08, 2026 Alzheimer’s disease is usually discussed in terms of amyloid and tau. But those pathologies do not arise in isolation. Aging biology sets the stage — and one of the most consequential, yet under-appreciated, contributors to age-related disease is cellular senescence. Senescent cells are…
Written by
-
Rapamycin & Low Dose Naltrexone
– a potentially powerful combination! Karin Dee Jul 28, 2025 Rapamycin + Low Dose Naltrexone (LDN) is a fascinating and potentially synergistic combo—especially for APOE4 carriers, where immune modulation is key to slowing neurodegeneration. Why This May Be Powerful in APOE4 APOE4 brains live in a state of chronic immune priming, with: Rapamycin helps recalibrate mTOR and microglial behavior,…
Written by
-
Shedding Light on the Brain: Red Light Therapy for Cognitive Health
Karin Dee Jul 21, 2025 In the realm of brain health and Alzheimer’s prevention, red light therapy (also called photobiomodulation or “PBM”) is generating quiet but widespread excitement. What was once fringe has become a serious contender in the cognitive longevity space—especially for APOE4 carriers and others seeking non-invasive tools for mitochondrial and neurovascular support.…
Written by
-
Powering the Brain: Mitochondrial Peptides & Alzheimer’s Prevention
Mitochondrial health is central to brain resilience Karin Dee Jul 19, 2025 When it comes to brain health—especially preventing Alzheimer’s disease—there’s one key system that often gets overlooked: our mitochondria. You might remember from school that mitochondria are the “powerhouses of the cell.” But they’re much more than that. In our brain, they: When mitochondria break…
Written by
-
APOE4, Alzheimer’s Risk, and What I’m Exploring
Understanding APOE4 and Alzheimer’s Risk APOE4 is the strongest genetic risk factor for Alzheimer’s disease – but it is not a diagnosis, and it is not a fixed outcome. APOE status is determined primarily by two SNPs (genetic markers): rs429358 and rs7412. In most direct-to-consumer genetic reports, APOE4/4 corresponds to rs429358 C/C and rs7412 C/C.…
Written by